NCT02220556CompletedNot Applicable
Evaluation of Different Analysis Methods for Circulating Tumor Cells, Circulating Endothelial Cell, and Circulating Tumor DNA in Patient Followed for a Tumoral Pathology
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Institut Curie
- Enrollment
- 360
- Locations
- 3
- Primary Endpoint
- CTC, CEC or ctDNA incidence
Study Overview
Brief Summary
Fifteen cohorts will be opened. Each cohort will explore one analysis method and/or tumoral type. Up to 50 patient can be included into each cohort.
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Single Group
- Primary Purpose
- Diagnostic
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •18 years old or more
- •Performance status from 0 to 4
- •Patient treated followed for histologically confirmed solid tumor type of any of these localization : breast, prostate, uterus, ovary, colon, lung, head and neck, melanoma.
- •Informed consent form signed.
Exclusion Criteria
- •Patient with history of other invasive cancer within 5 years.
- •Patient treated for any non-invasive cancer
- •Patient individually deprived of liberty or placed under the authority of a tutor
- •Geographical condition potentially preventing compliance with the study protocol.
Outcomes
Primary Outcomes
CTC, CEC or ctDNA incidence
Time Frame: 3 years
number of CTC or CEC in 7.5ml of blood
Secondary Outcomes
- CTC and CEC molecular characterization(3 years)
- Circulating tumor DNA (ctDNA) detection and quantification(3 years)
Investigators
Study Sites (3)
Loading locations...
Similar Trials
Active, not recruiting
Not Applicable
The iCat2, GAIN (Genomic Assessment Informs Novel Therapy) Consortium StudyPediatric Solid TumorNCT02520713Dana-Farber Cancer Institute825
Completed
Not Applicable
Histological Analysis Following Ulthera System Treatment for HyperhidrosisHyperhidrosisNCT01708551Ulthera, Inc59
Active, not recruiting
Phase 2
Phase-2 Dacomitinib Study on Patients With EGFR-Driven Advanced Solid Tumours With Low EGFR-AS1 IncRNA Expr or Other Novel Emerging BiomarkersAdvanced Solid TumoursHead and Neck Squamous Cell CarcinomaNon-small Cell Lung CancerNCT04946968National Cancer Centre, Singapore24
Recruiting
Not Applicable
Valid Biomarkers in Blood to Predict the Response to Therapy in Prostate Cancer PatientsProstate CancerNCT03408964Oncology Institute of Southern Switzerland600
Withdrawn
Not Applicable
Collection of Retrospective (Archival) Samples and Prospective Collection of Surplus Tissue and Blood SamplesCancerNCT02239575Global BioClinical